Forteo denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for forteo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Forteo on Medical-Necessity Grounds

A medical-necessity denial means Cigna's clinical review team concluded that the submitted documentation did not demonstrate that teriparatide (Forteo) is the appropriate level of treatment for your current clinical status — most commonly because the record appears to show insufficient severity, inadequate documentation of prior therapy failure, or a gap between what the prescriber asserts and what the submitted chart supports.

This is one of the most common — and most successfully overturned — denial types for teriparatide. The denial is almost always about documentation quality, not about whether you actually need the medication.

## Federal Appeal Framework

• Internal appeal: File within the deadline shown on your denial letter. Cigna must issue a decision within 30 days for prospective or concurrent non-urgent requests.
• External review (ACA §2719 / ERISA §503): If the internal appeal is denied, request independent external review within approximately 4 months of that decision. The IRO reviewer is an independent clinician unaffiliated with Cigna. If your health could be seriously jeopardized by delay, request expedited review (72-hour decision).

## Documentation to Gather

1. Diagnosis confirmation: DXA scan results with T-score and interpretation, any fracture history with imaging, and a physician statement of overall fracture risk. 2. Clinical severity: Physician notes explicitly documenting severity level, progression, and why your case meets the clinical threshold for anabolic therapy as described in the FDA prescribing label and applicable guidelines. 3. Prior-treatment history: A complete dated list of antiresorptive or other osteoporosis agents tried — name, dates, dose achieved, duration, reason for discontinuation or inadequate response. Gaps in this narrative are the single most common reason medical-necessity appeals fail. 4. Prescriber medical-necessity letter: A letter signed by the treating physician that directly addresses each criterion in Cigna's coverage policy and maps each to specific chart findings. 5. Applicable guidelines: Reference to the guideline body (e.g., AACE/ACE, Endocrine Society) supporting anabolic therapy for your documented risk level.

## Criteria-Mapping Structure

Download Cigna's current medical coverage policy for teriparatide and the FDA-approved prescribing label. List every stated requirement. Next to each requirement, write the specific chart entry, date, and provider name that satisfies it. Submit this as the first page of your appeal packet so the reviewer can verify necessity without searching through the full record.